93 results
Search Results
2. Mechanistic reasoning and informed consent.
- Author
-
Kennedy, Ashley and Malanowski, Sarah
- Subjects
ATTITUDE (Psychology) ,CONTRACEPTIVE drugs ,CRITICISM ,INFORMED consent (Medical law) ,MEDICAL practice ,THERAPEUTICS ,EVIDENCE-based medicine ,RANDOMIZED controlled trials ,PATIENTS' attitudes - Abstract
Evidence‐based medicine (EBM) proponents have argued that mechanistic evidence concerning medical treatments should be considered secondary to evidence derived from randomized controlled trials (RCTs). One common criticism of RCTs is that they often do not yield results that are generalizable to clinical practice, and that for clinical practice application, mechanistic evidence is needed. However, proponents of EBM have argued that mechanistic reasoning is often unreliable and thus not very useful. Here we suggest an important role of mechanistic explanation that has been left out of this discussion entirely, namely, its importance in a patient's decision of whether or not to take certain drugs. We argue that in certain cases, knowing how a treatment works is just as important for the patient as knowing whether it does. In this paper, we explore how and why giving patients mechanistic information can be an important factor in obtaining informed consent for medical treatment, focusing on the example case of hormonal contraceptives. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Neurodevelopmental outcome of nutritional intervention in newborn infants at risk of neurodevelopmental impairment: the Dolphin neonatal double-blind randomized controlled trial.
- Author
-
Andrew, Morag J., Montague‐Johnson, Christine, Laler, Karen, Baker, Bonny, Sullivan, Peter B., Parr, Jeremy R., Holmes, Jane, and Montague-Johnson, Christine
- Subjects
NEWBORN infants ,NEUROLOGICAL disorders ,DOCOSAHEXAENOIC acid ,RANDOMIZED controlled trials ,BLIND experiment ,NUCLEOTIDES ,CHOLINE ,PREMATURE infant disease prevention ,CHILD development ,COMPARATIVE studies ,DIET therapy ,PREMATURE infants ,PREMATURE infant diseases ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,THERAPEUTICS - Abstract
Copyright of Developmental Medicine & Child Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
4. Nutritional intervention and neurodevelopmental outcome in infants with suspected cerebral palsy: the Dolphin infant double-blind randomized controlled trial.
- Author
-
Andrew, Morag J., Montague‐Johnson, Christine, Laler, Karen, Baker, Bonny, Sullivan, Peter B., Parr, Jeremy R., Qi, Cathy, and Montague-Johnson, Christine
- Subjects
NEURODEVELOPMENTAL treatment for infants ,CEREBRAL palsy ,DOCOSAHEXAENOIC acid ,NUTRITION ,RANDOMIZED controlled trials ,CEREBRAL palsy treatment ,NUCLEOTIDES ,CHOLINE ,CHILD development ,COMPARATIVE studies ,DIET therapy ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,BLIND experiment ,DISEASE complications ,PSYCHOLOGY ,THERAPEUTICS - Abstract
Copyright of Developmental Medicine & Child Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
5. Efficacy of nutritional supplementation with omega-3 and omega-6 fatty acids in dry eye syndrome: a systematic review of randomized clinical trials.
- Author
-
Molina‐Leyva, Ignacio, Molina‐Leyva, Alejandro, and Bueno‐Cavanillas, Aurora
- Subjects
TREATMENT of dry eye syndromes ,THERAPEUTIC use of omega-3 fatty acids ,OMEGA-6 fatty acids ,DIETARY supplements ,SYSTEMATIC reviews ,RANDOMIZED controlled trials ,THERAPEUTICS - Abstract
Purpose To critically appraise scientific evidence regarding the efficacy of nutritional supplementation with omega-3 and omega-6 fatty acids for the treatment of dry eye syndrome (DES). Methods A systematic review of randomized clinical trials was performed. Two independent reviewers selected and analysed the scientific papers that met inclusion and exclusion criteria. Objective and subjective efficacy outcomes were assessed. Results The trials involved a total of 2591 patients in fifteen independent studies. All studies were published between 2005 and 2015. The supplements used were mostly omega-3 and omega-6 in different proportions. Subjective improvement was measured using mainly Ocular Surface Disease Index ( OSDI) test and Dry Eye Severity Score ( DESS) test: significant differences in favour of the experimental group were found in seven of the studies. The objective amelioration was assessed by lacrimal function parameters: Tear break-up time ( TBUT) significantly increased in nine studies and Schirmer's test in four studies. Conclusion We observed a discrete improvement in the parameters of tear function. Scientific evidence is not strong enough to systematically recommend the use of omega-3 and omega-6 fatty acids as a standalone treatment of DES independently from its aetiology. However, they could be considered as an effective alternative to topical treatment in patients with DES secondary to certain pathologies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Optimizing exposure-based CBT for anxiety disorders via enhanced extinction: Design and methods of a multicentre randomized clinical trial.
- Author
-
Heinig, Ingmar, Pittig, Andre, Richter, Jan, Hummel, Katrin, Alt, Isabel, Dickhöver, Kristina, Gamer, Jennifer, Hollandt, Maike, Koelkebeck, Katja, Maenz, Anne, Tennie, Sophia, Totzeck, Christina, Yang, Yunbo, Arolt, Volker, Deckert, Jürgen, Domschke, Katharina, Fydrich, Thomas, Hamm, Alfons, Hoyer, Jürgen, and Kircher, Tilo
- Subjects
MENTAL depression ,THERAPEUTICS ,DIAGNOSIS of mental depression ,COGNITIVE therapy ,PSYCHOPHYSIOLOGY ,BIOCHEMICAL mechanism of action ,RANDOMIZED controlled trials - Abstract
Exposure-based psychological interventions currently represent the empirically best established first line form of cognitive-behavioural therapy for all types of anxiety disorders. Although shown to be highly effective in both randomized clinical and other studies, there are important deficits: (1) the core mechanisms of action are still under debate, (2) it is not known whether such treatments work equally well in all forms of anxiety disorders, including comorbid diagnoses like depression, (3) it is not known whether an intensified treatment with more frequent sessions in a shorter period of time provides better outcome than distributed sessions over longer time intervals. This paper reports the methods and design of a large-scale multicentre randomized clinical trial (RCT) involving up to 700 patients designed to answer these questions. Based on substantial advances in basic research we regard extinction as the putative core candidate model to explain the mechanism of action of exposure-based treatments. The RCT is flanked by four add-on projects that apply experimental neurophysiological and psychophysiological, (epi)genetic and ecological momentary assessment methods to examine extinction and its potential moderators. Beyond the focus on extinction we also involve stakeholders and routine psychotherapists in preparation for more effective dissemination into clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Comparison of NB‐UVB combination therapy regimens for vitiligo: A systematic review and network meta‐analysis.
- Author
-
Zhu, Baohua, Liu, Chengjiang, Zhang, Lan, Wang, Jun, Chen, Mingling, and Wei, Yuegang
- Subjects
VITILIGO ,INTRAMUSCULAR injections ,RANDOMIZED controlled trials ,THERAPEUTICS ,CHINESE medicine - Abstract
Background: Vitiligo was an autoimmune disease and some guidelines for the management of vitiligo encouraged the use of NB‐UVB combination therapies to enhance repigmentation. Objectives: To compare the effectiveness of current NB‐UVB combination regimen at the improvement in repigmentation through a systematic review and network meta‐analysis. Methods: We searched the electronic databases for randomized controlled trials related to NB‐UVB combination therapy for vitiligo till October 2022. STATA15.0 software was applied to carrying out data analysis. Results: A total of 28 eligible studies involving 1194 participants were enrolled in the analysis. The NMA results revealed that compared with NB‐UVB, carboxytherapy [OR = 32.35, 95% CI (1.79, 586.05)], Er: YAG laser+ topical 5% 5‐FU [OR = 10.74, 95% CI (4.05, 28.49)], needling/micro‐needling [OR = 3.42, 95% CI (1.18, 9.88)], betamethasone intramuscular injection [OR = 3.08, 95% CI (1.17, 8.13)], topical tacrolimus [OR = 2.54, 95% CI (1.30, 4.94)], and oral Chinese herbal medicine compound [OR = 2.51, 95% CI (1.40, 4.50)] integrated with NB‐UVB were more efficacious in excellent to complete repigmentation response rate (≥75%). Besides, NB‐UVB+ Er: YAG laser+ topical 5% 5‐FU [OR = 0.17, 95% CI (0.04, 0.67)] and NB‐UVB+ needling/micro‐needling [OR = 0.24, 95% CI (0.06, 0.88)] were less likely evaluated as ineffective repigmentation response (≤25%). Conclusions: All combination therapies ranked higher than NB‐UVB monotherapy in inducing successful repigmentation and avoiding failed treatment in patients with vitiligo. Comprehensive consideration, NB‐UVB+ Er: YAG laser+ topical 5% 5‐FU and NB‐UVB+ needling/microneedling would be the preferred therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Restrictive fluids versus standard care in adults with sepsis in the emergency department (REFACED): A multicenter, randomized feasibility trial.
- Author
-
Jessen, Marie K., Andersen, Lars W., Thomsen, Marie‐Louise H., Kristensen, Peter, Hayeri, Wazhma, Hassel, Ranva E., Messerschmidt, Tina G., Sølling, Christoffer G., Perner, Anders, Petersen, Jens Aage K., and Kirkegaard, Hans
- Subjects
THERAPEUTICS ,RESEARCH ,PILOT projects ,FLUID therapy ,HOSPITAL emergency services ,CONFIDENCE intervals ,HEALTH outcome assessment ,SEPSIS ,RANDOMIZED controlled trials ,BLOOD plasma substitutes ,DESCRIPTIVE statistics ,PATIENT care ,STATISTICAL sampling - Abstract
Background: Fluid treatment in sepsis is a challenge and clinical equipoise exists regarding intravenous (IV) volumes. We aimed to determine whether a 24‐h protocol restricting IV fluid was feasible in adult patients with sepsis without shock presenting to the emergency department (ED). Methods: The REFACED Sepsis trial is an investigator‐initiated, multicenter, randomized, open‐label, feasibility trial, assigning sepsis patients without shock to 24 h of restrictive, crystal IV fluid administration or standard care. In the IV fluid restriction group fluid boluses were only permitted if predefined criteria for hypoperfusion occurred. Standard care was at the discretion of the treating team. The primary outcome was total IV crystalloid fluid volumes at 24 h after randomization. Secondary outcomes included total fluid volumes, feasibility measures, and patient‐centered outcomes. Results: We included 123 patients (restrictive 61 patients and standard care 62 patients) in the primary analysis. A total of 32% (95% confidence interval [CI] 28%–37%) of eligible patients meeting all inclusion criteria and no exclusion criteria were included. At 24 h, the mean (±SD) IV crystalloid fluid volumes were 562 (±1076) ml versus 1370 (±1438) ml in the restrictive versus standard care group (mean difference –801 ml, 95% CI −1257 to −345 ml, p = 0.001). Protocol violations occurred in 21 (34%) patients in the fluid‐restrictive group. There were no differences between groups in adverse events, use of mechanical ventilation or vasopressors, acute kidney failure, length of stay, or mortality. Conclusions: A protocol restricting IV crystalloid fluids in ED patients with sepsis reduced 24‐h fluid volumes compared to standard care. A future trial powered toward patient‐centered outcomes appears feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. A review of clinical efficacy data supporting emergency use authorization for COVID‐19 therapeutics and lessons for future pandemics.
- Author
-
Yoo, Seo‐Hyun, Kim, Lauren, Lu, Michelle, Nagoshi, Kira, and Namchuk, Mark N.
- Subjects
COVID-19 ,THERAPEUTICS ,COVID-19 pandemic ,RANDOMIZED controlled trials - Abstract
Emergency Use Authorization (EUA) allows the US Food and Drug Administration (FDA) to expedite the availability of therapeutics in the context of a public health emergency. To date, an evidentiary standard for clinical efficacy to support an EUA has not yet been established. This review examines the clinical data submitted in support of EUA for antiviral and anti‐inflammatory therapeutics for coronavirus disease 2019 (COVID‐19) through December of 2021 and the resilience of the authorization as new clinical data arose subsequent to the authorization. In the vast majority of cases, EUA was supported by at least one well‐powered randomized controlled trial (RCT) where statistically significant efficacy was demonstrated. This included branded medications already approved for use outside of the context of COVID‐19. When used, the standard of a single RCT seemed to provide adequate evidence of clinical efficacy, such that subsequent clinical studies generally supported or expanded the EUA of the therapeutic in question. The lone generic agent that was granted EUA (chloroquine/hydroxychloroquine) was not supported by a well‐controlled RCT, and the EUA was withdrawn within 3 months time. This highlighted not only the ambiguity of the EUA standard, but also the need to provide avenues through which high quality clinical evidence for the efficacy of a generic medication could be obtained. Therefore, maintaining the clinical trial networks assembled during the COVID‐19 pandemic could be a critical component of our preparation for future pandemics. Consideration could also be given to establishing a single successful RCT as regulatory guidance for obtaining an EUA. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
- Author
-
Samer, CF, Daali, Y, Wagner, M, Hopfgartner, G, Eap, CB, Rebsamen, MC, Rossier, MF, Hochstrasser, D, Dayer, P, Desmeules, JA, Samer, C F, Eap, C B, Rebsamen, M C, Rossier, M F, and Desmeules, J A
- Subjects
GENETIC polymorphisms ,DRUG interactions ,OXYCODONE ,DRUG efficacy ,PHARMACODYNAMICS ,KETOCONAZOLE ,ORAL drug administration ,CYTOCHROME P-450 ,THERAPEUTIC use of narcotics ,ANALGESICS ,BIOTRANSFORMATION (Metabolism) ,CLINICAL trials ,COMPARATIVE studies ,CROSSOVER trials ,ENZYME inhibitors ,RESEARCH methodology ,MEDICAL cooperation ,PSYCHOLOGY of movement ,NARCOTICS ,OXIDOREDUCTASES ,REFLEXES ,RESEARCH ,PHENOTYPES ,EVALUATION research ,RANDOMIZED controlled trials ,BLIND experiment ,PAIN threshold ,GENOTYPES ,CHEMICAL inhibitors ,THERAPEUTICS - Abstract
Background and Purpose: The major drug-metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A. A high interindividual variability in the activity of these enzymes because of genetic polymorphisms and/or drug-drug interactions is well established. The possible role of an active metabolite in the pharmacodynamics of oxycodone has been questioned and the importance of CYP3A-mediated effects on the pharmacokinetics and pharmacodynamics of oxycodone has been poorly explored.Experimental Approach: We conducted a randomized crossover (five arms) double-blind placebo-controlled study in 10 healthy volunteers genotyped for CYP2D6. Oral oxycodone (0.2 mg x kg(-1)) was given alone or after inhibition of CYP2D6 (with quinidine) and/or of CYP3A (with ketoconazole). Experimental pain (cold pressor test, electrical stimulation, thermode), pupil size, psychomotor effects and toxicity were assessed.Key Results: CYP2D6 activity was correlated with oxycodone experimental pain assessment. CYP2D6 ultra-rapid metabolizers experienced increased pharmacodynamic effects, whereas cold pressor test and pupil size were unchanged in CYP2D6 poor metabolizers, relative to extensive metabolizers. CYP2D6 blockade reduced subjective pain threshold (SPT) for oxycodone by 30% and the response was similar to placebo. CYP3A4 blockade had a major effect on all pharmacodynamic assessments and SPT increased by 15%. Oxymorphone C(max) was correlated with SPT assessment (rho(S)= 0.7) and the only independent positive predictor of SPT. Side-effects were observed after CYP3A4 blockade and/or in CYP2D6 ultra-rapid metabolizers.Conclusions and Implications: The modulation of CYP2D6 and CYP3A activities had clear effects on oxycodone pharmacodynamics and these effects were dependent on CYP2D6 genetic polymorphism. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
11. Economic evaluation of a reduced dosage of ready‐to‐use therapeutic foods to treat uncomplicated severe acute malnourished children aged 6–59 months in Burkina Faso.
- Author
-
N'Diaye, Dieynaba S., Wassonguema, Bibata, Nikièma, Victor, Kangas, Suvi T., and Salpéteur, Cécile
- Subjects
STATISTICS ,CONFIDENCE intervals ,MULTIVARIATE analysis ,MEDICAL care costs ,HEALTH outcome assessment ,COST benefit analysis ,RANDOMIZED controlled trials ,BURKINABE ,MALNUTRITION ,DESCRIPTIVE statistics ,RESEARCH funding ,STATISTICAL sampling ,DATA analysis software ,ELEMENTAL diet ,OUTPATIENT services in hospitals ,THERAPEUTICS - Abstract
Ready‐to‐use therapeutic foods (RUTF) used to treat children with severe acute malnutrition (SAM) are costly, and the prescribed dosage has not been optimized. The MANGO trial, implemented by Action Contre la Faim in Burkina Faso, proved the non‐inferiority of a reduced RUTF dosage in community‐based treatment of uncomplicated SAM. We performed a cost‐minimization analysis to assess the economic impact of transitioning from the standard to the reduced RUTF dose. We used a decision‐analytic model to simulate a cohort of 399 children/arm, aged 6–59 months and receiving SAM treatment. We adopted a societal perspective: direct medical costs (drugs, materials and staff time), non‐medical costs (caregiver expenses) and indirect costs (productivity loss) in 2017 international US dollar were included. Data were collected through interviews with 35 caregivers and 20 informants selected through deliberate sampling and the review trial financial documents. The overall treatment cost for 399 children/arm was $36,550 with the standard and $30,411 with the reduced dose, leading to $6,140 (16.8%) in cost savings ($15.43 saved/child treated). The cost/consultation was $11.6 and $9.6 in the standard and reduced arms, respectively, with RUTF accounting for 56.2% and 47.0% of the total. The savings/child treated was $11.4 in a scenario simulating the Burkinabè routine SAM treatment outside clinical trial settings. The reduced RUTF dose tested in the MANGO trial resulted in significant cost savings for SAM treatment. These results are useful for decision makers to estimate potential economic gains from an optimized SAM treatment protocol in Burkina Faso and similar contexts. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. The impact of a physician's recommendation and gender on informed decision making: A randomized controlled study in a simulated decision situation.
- Author
-
Meinhardt, Anna Lea, Eggeling, Marie, Cress, Ulrike, Kimmerle, Joachim, and Bientzle, Martina
- Subjects
THERAPEUTICS ,STATISTICAL power analysis ,RESEARCH ,ANALYSIS of variance ,PATIENT decision making ,PHYSICIAN-patient relations ,ATTITUDE (Psychology) ,PHYSICAL therapy ,OPERATIVE surgery ,MULTIVARIATE analysis ,PATIENT satisfaction ,PATIENTS' attitudes ,RANDOMIZED controlled trials ,SEX distribution ,DECISION making ,ANTERIOR cruciate ligament injuries ,HEALTH ,INFORMATION resources ,QUESTIONNAIRES ,CLINICAL competence ,RESEARCH funding ,DESCRIPTIVE statistics ,SOCIAL skills ,STATISTICAL correlation ,DATA analysis software ,VIDEO recording - Abstract
Objective: This study examined the influence of physicians' recommendations and gender on the decision‐making process in a preference‐sensitive situation. Methods: N = 201 participants were put in a hypothetical scenario in which they suffered from a rupture of the anterior cruciate ligament (ACL). They received general information on two equally successful treatment options for this injury (surgery vs physiotherapy) and answered questions regarding their treatment preference, certainty and satisfaction regarding their decision and attitude towards the treatment options. Then, participants watched a video that differed regarding physician's recommendation (surgery vs physiotherapy) and physician's gender (female vs male voice and picture). Afterwards, they indicated again their treatment preference, certainty, satisfaction and attitude, as well as the physician's professional and social competence. Results: Participants changed their treatment preferences in the direction of the physician's recommendation (P <.001). Decision certainty (P <.001) and satisfaction (P <.001) increased more strongly if the physician's recommendation was congruent with the participant's prior attitude than if the recommendation was contrary to the participant's prior attitude. Finally, participants' attitudes towards the recommended treatment became more positive (surgery recommendation: P <.001; physiotherapy recommendation: P <.001). We found no influence of the physician's gender on participants' decisions, attitudes, or competence assessments. Conclusion: This research indicates that physicians should be careful with recommendations when aiming for shared decisions, as they might influence patients even if the patients have been made aware that they should take their personal preferences into account. This could be particularly problematic if the recommendation is not in line with the patient's preferences. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta‐analysis.
- Author
-
Yoon, Ha Young, Lee, Nari, Seong, Jong‐Mi, and Gwak, Hye Sun
- Subjects
PRASUGREL ,DRUG-eluting stents ,THERAPEUTICS ,CORONARY disease ,ALLELES ,CARDIOVASCULAR diseases ,RANDOMIZED controlled trials - Abstract
Aim: We performed a systematic review and meta‐analysis to compare the efficacy and safety of ticagrelor and prasugrel with those of clopidogrel in CYP2C19 reduced‐metabolizers. Methods: PubMed, Cochrane and Web of Science were systematically searched for randomized controlled trials or cohort studies up to January 2020. The primary endpoint was major adverse cardiovascular events (MACE), including cardiovascular (CV) death, all‐cause death, myocardial infarction (MI), stent thrombosis and stroke. The secondary endpoint was bleeding. Pooled effects were measured by relative risk (RR) with 95% confidence intervals (CIs). Publication bias was evaluated with Egger's regression test and adjusted by trim and fill method. Results: Twelve studies comprising 5829 CV patients with CYP2C19 loss‐of‐function alleles were included. Patients who received ticagrelor or prasugrel showed a lower risk of MACE than those who received clopidogrel (RR 0.524; 95% CI: 0.375, 0.731). The former also had lower risks of CV death (RR 0.409; 95% CI: 0.177, 0.946), all‐cause death (RR 0.441; 95% CI: 0.263, 0.739), MI (RR 0.554; 95% CI: 0.414, 0.741) and stent thrombosis (RR 0.587; 95% CI: 0.348, 0.988) than the latter patient group. The risk of stroke was not significantly different between patients receiving the alternatives and those receiving clopidogrel (RR 0.605; 95% CI: 0.257, 1.425). Major and minor bleeding risk was not significantly different between patients treated with alternatives and clopidogrel (RR 1.019; 95% CI: 0.827, 1.260 and RR 1.235; 95% CI: 0.581, 2.628, respectively). Conclusion: CYP2C19 reduced‐metabolizers can expect better clinical outcome on using prasugrel or ticagrelor rather than clopidogrel. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial.
- Author
-
Saag, Kenneth G., Pannacciulli, Nicola, Butler, Peter W., Yin, Xiang, Geusens, Piet, Adachi, Jonathan D., Messina, Osvaldo D., Morales‐Torres, Jorge, Emkey, Ronald, and Lems, Willem F.
- Subjects
DENOSUMAB ,CALCIUM ,THERAPEUTIC use of vitamin D ,DIPHOSPHONATES ,BONE fractures ,GLUCOCORTICOIDS ,MONOCLONAL antibodies ,OSTEOPOROSIS ,STATISTICAL sampling ,BONE density ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,DESCRIPTIVE statistics ,THERAPEUTICS - Abstract
Objective: Clinical trial results have shown that, in glucocorticoid‐treated patients, treatment with denosumab 60 mg subcutaneously once every 6 months (Q6M) increased spine and hip bone mineral density (BMD) at month 12 significantly more than treatment with risedronate 5 mg orally once daily (QD). The present analysis was performed to compare efficacy and characterize safety through month 24. Methods: This phase III study enrolled men and women ≥18 years old who had received ≥7.5 mg daily prednisone or equivalent for <3 months (glucocorticoid‐initiating) or for ≥3 months (glucocorticoid‐continuing) before screening. All patients <50 years old had a history of osteoporotic fracture. Glucocorticoid‐continuing patients ≥50 years old had T scores of −2.0 or less (or −1.0 or less with fracture history). Patients were randomized (1:1) to receive denosumab 60 mg subcutaneously Q6M or risedronate 5 mg orally QD for 24 months, with daily calcium and vitamin D. Results: Of 795 patients, 590 (74.2%) completed the study (in the glucocorticoid‐initiating group, 109 of 145 patients treated with denosumab and 117 of 145 patients treated with risedronate; in the glucocorticoid‐continuing group, 186 of 253 patients treated with denosumab and 178 of 252 patients treated with risedronate). Denosumab was superior to risedronate in increasing lumbar spine and total hip BMD at all time points assessed, among glucocorticoid‐initiating patients (24‐month lumbar spine: BMD increase of 6.2% versus 1.7%, respectively [P < 0.001]; 24‐month total hip: BMD increase of 3.1% versus 0.0% [P < 0.001]) and among glucocorticoid‐continuing patients (24‐month lumbar spine: BMD increase of 6.4% versus 3.2% [P < 0.001]; 24‐month total hip: BMD increase of 2.9% versus 0.5% [P < 0.001]). Adverse events, serious adverse events (including infections), and fractures were similar between treatment groups. Conclusion: Denosumab was superior to risedronate in terms of increases in spine and hip BMD through month 24, and the safety profile was similar between treatment groups. Denosumab may offer a new osteoporosis treatment option for glucocorticoid‐treated patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department.
- Author
-
Cole, Jon B, Klein, Lauren R., Mullinax, Samuel Z., Nordstrom, Kimberly D., Driver, Brian E., Wilson, Michael P., and Miner, James R.
- Subjects
DIAGNOSIS of schizophrenia ,LORAZEPAM ,DIAGNOSIS of bipolar disorder ,HALOPERIDOL ,ACADEMIC medical centers ,ANTIPSYCHOTIC agents ,COMBINATION drug therapy ,HOSPITAL emergency services ,HOSPITAL medical staff ,INFORMED consent (Medical law) ,MEDICAL appointments ,METROPOLITAN areas ,AGITATION (Psychology) ,RANDOMIZED controlled trials ,ACUTE diseases ,INHALATION administration ,THERAPEUTICS - Abstract
Background: Acute agitation in the emergency department (ED) represents a danger to both patients and their caregivers. Medication is often needed, and few high‐quality randomized trials have evaluated the optimal drugs for this vulnerable population. In the United States, as of 2017, randomized trials of drugs typically cannot be conducted under Waiver of Consent (46 CFR 45.116), and Exception From Informed Consent trials (21 CFR 50.24) are limited to life‐threatening conditions, are onerous, and require filing an investigational new drug application with the FDA. We sought to conduct a randomized double‐dummy trial of inhaled loxapine versus intramuscular haloperidol + lorazepam for acute agitation in the ED by obtaining consent in advance ("preconsent") in patients at risk of future agitation, allowing study drug administration up to 3 years later if the patient presented with acute agitation. Objective: We sought to report the successful enrollment rate of patients preconsented at an earlier ED visit for this trial. Methods: This was an analysis of patients age 18 to 64 with bipolar I disorder or schizophrenia preconsented for enrollment in the trial (clinicaltrials.gov, NCT02877108) conducted at a single urban academic center seeing approximately 60,000 patients per year. Eligible patients were assessed for capacity to consent by trained research associates, and informed consent was obtained at an ED visit for the possibility of administering drugs for agitation within the next 3 years. In the event the patient later presented to the ED and the attending physician deemed the patient required treatment for acute agitation, preconsent was confirmed and study drug would be administered. Results: Over 67 days, 1,461 patients were screened in the ED, 269 had bipolar I or schizophrenia, 194 of whom had a contraindication to inhaled loxapine leaving 75 eligible patients; preconsent was obtained in 43 patients. Four additional patients who had not preconsented were consented for the trial in real time (three by surrogate, one patient had capacity while agitated) resulting in a total of 47 consented patients. Of these 47, a total of 12 were later removed from the study: 10 patients had unrecognized exclusion criteria for inhaled loxapine, one preconsented patient contacted the investigators at a later date and asked to be removed, and one surrogate revoked consent immediately after providing it. Only two patients were successfully enrolled, neither by preconsent: one was enrolled via a surrogate the day of enrollment, and the other was mildly agitated and had capacity to consent. The remaining patient with a valid surrogate consent did not receive study medication. Conclusions: Utilization of preconsent to enroll patients in a randomized trial of treatments for acute agitation in the ED requires substantial resources and may not be feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Variation in outcome reporting in randomized controlled trials of interventions for prevention and treatment of fetal growth restriction.
- Author
-
Sileo, F., Townsend, R., Khalil, A., Papageorghiou, A., Kenny, L., Bloomfield, F., Daly, M., Stocker, L., Kumbay, H., Healy, P., Devane, D., Gordijn, S., Beune, I., Ganzevoort, W., and Baschat, A.
- Subjects
FETAL development ,RANDOMIZED controlled trials ,THERAPEUTICS ,BIRTH weight ,GESTATIONAL age - Abstract
Objective: Although fetal growth restriction (FGR) is well known to be associated with adverse outcomes for the mother and offspring, effective interventions for the management of FGR are yet to be established. Trials reporting interventions for the prevention and treatment of FGR may be limited by heterogeneity in the underlying pathophysiology. The aim of this study was to conduct a systematic review of outcomes reported in randomized controlled trials (RCTs) assessing interventions for the prevention or treatment of FGR, in order to identify and categorize the variation in outcome reporting.Methods: MEDLINE, EMBASE and The Cochrane Library were searched from inception until August 2018 for RCTs investigating therapies for the prevention and treatment of FGR. Studies were assessed systematically and data on outcomes that were reported in the included studies were extracted and categorized. The methodological quality of the included studies was assessed using the Jadad score.Results: The search identified 2609 citations, of which 153 were selected for full-text review and 72 studies (68 trials) were included in the final analysis. There were 44 trials relating to the prevention of FGR and 24 trials investigating interventions for the treatment of FGR. The mean Jadad score of all studies was 3.07, and only nine of them received a score of 5. We identified 238 outcomes across the included studies. The most commonly reported were birth weight (88.2%), gestational age at birth (72.1%) and small-for-gestational age (67.6%). Few studies reported on any measure of neonatal morbidity (27.9%), while adverse effects of the interventions were reported in only 17.6% of trials.Conclusions: There is significant variation in outcome reporting across RCTs of therapies for the prevention and treatment of FGR. The clinical applicability of future research would be enhanced by the development of a core outcome set for use in future trials. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
17. Ultrasonography effectiveness of the vibration vs cryotherapy added to an eccentric exercise protocol in patients with chronic mid‐portion Achilles tendinopathy: A randomised clinical trial.
- Author
-
Romero‐Morales, Carlos, Javier Martín‐Llantino, Pedro, Calvo‐Lobo, César, Palomo‐López, Patricia, López‐López, Daniel, Fernández‐Carnero, Josué, and Rodríguez‐Sanz, David
- Subjects
COLD therapy ,EXERCISE therapy ,MEDICAL protocols ,MUSCLE contraction ,VIBRATION (Mechanics) ,RANDOMIZED controlled trials ,ACHILLES tendinitis ,CROSS-sectional method ,THERAPEUTICS - Abstract
Tendinopathy is a very common disease in the general population as well as in athletes. The aim of the present study was to examine the tendon thickness and cross‐sectional area (CSA) in subjects with chronic mid‐portion Achilles tendinopathy (AT) who engaged in either an eccentric exercise (EE) programme with vibration training or an EE programme combined with cryotherapy. A sample of 61 patients with chronic mid‐portion AT were recruited and divided into two groups: EE programme vibration training (n = 30) and EE programme combined with cryotherapy (n = 31). Three ultrasound assessments were performed: pre‐intervention and at 4, and at 12 weeks. The comparison of thickness and CSA measures at baseline, 4, and 12 weeks showed a significant (P < 0.05) increase at 0, 2, 4, and 6 cm in maximal isometric contraction and at rest in subjects with chronic mid‐portion AT. The EE vibration training resulted in a statistically significant CSA increase compared with the cryotherapy group in patients with chronic mid‐portion AT. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Nebulized Terbutaline and Ipratropium Bromide Versus Terbutaline Alone in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Requiring Noninvasive Ventilation: A Randomized Double‐blind Controlled Trial.
- Author
-
Beltaief, Kaouthar, Msolli, Mohamed Amine, Zorgati, Asma, Sekma, Adel, Fakhfakh, Marwen, Marzouk, Maryem Ben, Boubaker, Hamdi, Grissa, Mohamed Habib, Methamem, Mehdi, Boukef, Riadh, Belguith, Asma, Bouida, Wahid, Nouira, Semir, and Heard, Kennon J.
- Subjects
OBSTRUCTIVE lung disease treatment ,BLOOD gases analysis ,CONFIDENCE intervals ,DYSPNEA ,HOSPITAL care ,LENGTH of stay in hospitals ,HOSPITAL admission & discharge ,HOSPITAL emergency services ,INTENSIVE care units ,PATIENTS ,TRACHEA intubation ,VENTILATION ,VITAL signs ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,DISEASE exacerbation ,IPRATROPIUM (Drug) ,HOSPITAL mortality ,TERBUTALINE ,EVALUATION ,THERAPEUTICS - Abstract
Background: Short‐acting β2‐agonists are the mainstay of treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the emergency department (ED). It is still unclear whether the addition of short‐acting anticholinergics is clinically more effective care compared to treatment with β2‐agonists alone in patients with hypercapnic AECOPD. Objective: The objective was to evaluate whether combining ipratropium bromide (IB) to terbutaline reduces hospital and intensive care unit (ICU) admission rates compared to terbutaline alone in AECOPD hypercapnic patients. Methods: In this double‐blind controlled trial, patients who were admitted to the ED for AECOPD requiring noninvasive ventilation (NIV) were randomized to receive either 5 mg of nebulized terbutaline combined to 0.5 mg of IB (terbutaline/IB group, n = 115) or 5 mg of terbutaline sulfate (terbutaline group, n = 117). Nebulization was repeated every 20 minutes for the first hour and every 4 hours within the first day. Primary outcomes were the rate of hospital admission and need for endotracheal intubation within the first 24 hours of the start of the experimental treatment. Secondary outcomes included changes from baseline of dyspnea, physiologic variables, length of hospital stay, ICU admission rate, and 7‐day mortality. Results: The two groups were similar regarding baseline demographic and clinical characteristics. Hospital admission was observed in 70 patients (59.8%) in the terbutaline/IB group and in 75 patients (65.2%) in the terbutaline group (respiratory rate [RR] = 1.09, 95% confidence interval [CI] = 0.93 to 1.27, p = 0.39). ICU admission was required in 37 (32.2%) patients in the terbutaline/IB group and 30 patients (25.6%) in terbutaline group (RR = 1.25, 95% CI = 1.02 to 1.54, p = 0.27). There were no significant differences in dyspnea score, blood gas parameters changes, vital signs improvement, and 7‐day death rate between both groups. Conclusion: In patients admitted to the ED for AECOPD requiring NIV, combination of nebulized IB and terbutaline did not reduce hospital admission and need to ICU care. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. The HEART Pathway Randomized Controlled Trial One‐year Outcomes.
- Author
-
Stopyra, Jason P., Riley, Robert F., Hiestand, Brian C., Russell, Gregory B., Hoekstra, James W., Lefebvre, Cedric W., Nicks, Bret A., Cline, David M., Askew, Kim L., Elliott, Stephanie B., Herrington, David M., Burke, Gregory L., Miller, Chadwick D., Mahler, Simon A., and Diercks, Deborah B.
- Subjects
CHEST pain diagnosis ,CHEST pain treatment ,ACUTE diseases ,TROPONIN ,CARDIAC arrest ,CONFIDENCE intervals ,CORONARY artery bypass ,FISHER exact test ,HOSPITAL care ,HOSPITAL emergency services ,MEDICAL appointments ,MEDICAL care ,MEDICAL care use ,MYOCARDIAL infarction ,MYOCARDIAL revascularization ,PATIENTS ,PATIENT safety ,RISK assessment ,PSYCHOLOGICAL stress ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PREDICTIVE tests ,CORONARY angiography ,DIAGNOSIS ,THERAPEUTICS - Abstract
Objective: The objective was to determine the impact of the HEART Pathway on health care utilization and safety outcomes at 1 year in patients with acute chest pain. Methods: Adult emergency department (ED) patients with chest pain (N = 282) were randomized to the HEART Pathway or usual care. In the HEART Pathway arm, ED providers used the HEART score and troponin measures (0 and 3 hours) to risk stratify patients. Usual care was based on American College of Cardiology/American Heart Association guidelines. Major adverse cardiac events (MACE—cardiac death, myocardial infarction [MI], or coronary revascularization), objective testing (stress testing or coronary angiography), and cardiac hospitalizations and ED visits were assessed at 1 year. Randomization arm outcomes were compared using Fisher's exact tests. Results: A total of 282 patients were enrolled, with 141 randomized to each arm. MACE at 1 year occurred in 10.6% (30/282): 9.9% in the HEART Pathway arm (14/141; 10 MIs, four revascularizations without MI) versus 11.3% in usual care (16/141; one cardiac death, 13 MIs, two revascularizations without MI; p = 0.85). Among low‐risk HEART Pathway patients, 0% (0/66) had MACE, with a negative predictive value (NPV) of 100% (95% confidence interval = 93%–100%). Objective testing through 1 year occurred in 63.1% (89/141) of HEART Pathway patients compared to 71.6% (101/141) in usual care (p = 0.16). Nonindex cardiac‐related hospitalizations and ED visits occurred in 14.9% (21/141) and 21.3% (30/141) of patients in the HEART Pathway versus 10.6% (15/141) and 16.3% (23/141) in usual care (p = 0.37, p = 0.36). Conclusions: The HEART Pathway had a 100% NPV for 1‐year safety outcomes (MACE) without increasing downstream hospitalizations or ED visits. Reduction in 1‐year objective testing was not significant. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Barriers and enablers to patient recruitment for randomised controlled trials on treatment of chronic wounds: A systematic review.
- Author
-
Bugeja, Lyndal, Low, Jac Kee, McGinnes, Rosemary A, Team, Victoria, Sinha, Sankar, and Weller, Carolina
- Subjects
CHRONIC wounds & injuries ,CINAHL database ,INFORMATION storage & retrieval systems ,MEDICAL databases ,MEDICAL information storage & retrieval systems ,PSYCHOLOGY information storage & retrieval systems ,MEDLINE ,SYSTEMATIC reviews ,RANDOMIZED controlled trials ,PATIENT selection ,THERAPEUTICS - Abstract
Randomised controlled trials represent the gold standard in intervention efficacy evaluation. However, suboptimal recruitment affects completion and the power of a therapeutic trial in detecting treatment differences. We conducted a systematic review to examine the barriers and enablers to patient recruitment for randomised controlled trials on chronic wound treatment. Review registration was under PROSPERO 2017:CRD42017062438. We conducted a systematic search of Ovid MEDLINE, EBSCOhost CINAHL, Ovid Cochrane Library, Ovid EMBASE, and Ovid PsycINFO databases in June 2017 for chronic wound treatment randomised controlled trials. Twenty‐seven randomised controlled trials or qualitative studies met the inclusion criteria. Among the 24 randomised controlled trials, 21 were assessed as low quality in relation to recruitment, and 3 were assessed as high quality. All 27 studies reported barriers to recruitment in chronic wound randomised controlled trials. The reported barriers to recruitment were: study‐related, patient‐related, clinician‐related, health system‐related, and/or operational‐related. No study reported recruitment enablers. To enhance randomised controlled trial recruitment, we propose the need for improved integration of research and clinical practice. To alleviate the problems arising from inadequate reporting of randomised controlled trials, the Consolidated Standards of Reporting Trials Statement could include an additional item on recruitment barriers. This approach will allow for increased awareness of the potential barriers to recruitment for Randomised controlled trials (RCTs) in both wound management and other health care research. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Ghanaian parents' perceptions of pre and postnatal nutrient supplements and their effects.
- Author
-
Adams, Katherine P., Young, Rebecca R., Dewey, Kathryn G., Okronipa, Harriet, Kumordzie, Sika, Ocansey, Maku E., Adu‐Afarwuah, Seth, Arimond, Mary, Oaks, Brietta M., and Vosti, Stephen A.
- Subjects
THERAPEUTIC use of folic acid ,LIPIDS ,THERAPEUTIC use of iron ,MICRONUTRIENTS ,PHARMACEUTICAL encapsulation ,COMPARATIVE studies ,FATHERS ,DIETARY supplements ,INFANT nutrition ,LACTATION ,LONGITUDINAL method ,MOTHERS ,NUTRITIONAL requirements ,PRENATAL care ,PROBABILITY theory ,PUERPERIUM ,SURVEYS ,LOGISTIC regression analysis ,QUANTITATIVE research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PARENT attitudes ,DESCRIPTIVE statistics ,ECONOMICS ,THERAPEUTICS - Abstract
Abstract: Small‐quantity lipid‐based nutrient supplements (SQ‐LNS) have been studied in efficacy and effectiveness trials, but little is known about how parents perceive the products and their effects. In a randomised trial in Ghana, efficacy of SQ‐LNS provided to women during pregnancy and the first 6 months postpartum and to their children from 6 to 18 months of age was assessed by comparison with iron‐folic acid (IFA) capsules and multiple micronutrient (MMN) capsules provided to women. In a follow‐up study conducted when the index children from the original trial were between 4 and 6 years of age, we used survey‐based methods to assess retrospective and current parental perceptions of nutrient supplements generally and of SQ‐LNS and their effects compared with perceptions IFA and MMN capsules. Most parents perceived that the assigned supplements (SQ‐LNS, IFA, or MMN) positively impacted the mother during pregnancy (approximately 89% of both mothers and fathers) and during lactation (84% of mothers and 86% of fathers). Almost all (≥90%) of mothers and fathers perceived that the assigned supplement positively impacted the index child and expected continued positive impacts on the child's health and human capital into the future. A smaller percentage of parents perceived negative impacts of the supplements (7%–17% of mothers and 4%–12% of fathers). Perceptions of positive impacts and of negative impacts did not differ by intervention group. The results suggest that similar populations would likely be receptive to programs to deliver SQ‐LNS or micronutrient capsules. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow‐up trial.
- Author
-
Zelen, Charles M., Orgill, Dennis P., Serena, Thomas E., Galiano, Robert E., Carter, Marissa J., DiDomenico, Lawrence A., Keller, Jennifer, Kaufman, Jarrod P., and Li, William W.
- Subjects
DIABETIC foot ,CHRONIC wounds & injuries ,COMBINED modality therapy ,COST effectiveness ,DERMIS ,HOMOGRAFTS ,LONGITUDINAL method ,MEDICAL quality control ,MEDICAL care costs ,MEDICAL cooperation ,MEDICAL screening ,MEETINGS ,RESEARCH ,WOUND healing ,RANDOMIZED controlled trials ,DISEASE incidence ,ADVERSE health care events ,SURGERY ,THERAPEUTICS - Abstract
Aseptically processed human reticular acellular dermal matrix (HR‐ADM) has been previously shown to improve wound closure in 40 diabetic patients with non‐healing foot ulcers. The study was extended to 40 additional patients (80 in total) to validate and extend the original findings. The entire cohort of 80 patients underwent appropriate offloading and standard of care (SOC) during a 2‐week screening period and, after meeting eligibility criteria, were randomised to receive weekly applications of HR‐ADM plus SOC or SOC alone for up to 12 weeks. The primary outcome was the proportion of wounds closed at 6 weeks. Sixty‐eight percent (27/40) in the HR‐ADM group were completely healed at 6 weeks compared with 15% (6/40) in the SOC group. The proportions of wounds healed at 12 weeks were 80% (34/40) and 30% (12/40), respectively. The mean time to heal within 12 weeks was 38 days for the HR‐ADM group and 72 days for the SOC group. There was no incidence of increased adverse or serious adverse events between groups or any graft‐related adverse events. The mean and median HR‐ADM product costs at 12 weeks were $1200 and $680, respectively. HR‐ADM is clinically superior to SOC, is cost effective relative to other comparable treatment modalities, and is an efficacious treatment for chronic non‐healing diabetic foot ulcers. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Current behavioral assessments of movement disorders in children.
- Author
-
Asakawa, Tetsuya, Sugiyama, Kenji, Nozaki, Takao, Sameshima, Tetsuro, Kobayashi, Susumu, Wang, Liang, Hong, Zhen, Chen, Shu‐Jiao, Li, Can‐Dong, Ding, Ding, and Namba, Hiroki
- Subjects
MOVEMENT disorders in children ,BEHAVIORAL assessment ,VIRTUAL reality ,RANDOMIZED controlled trials ,DIAGNOSIS ,THERAPEUTICS - Abstract
Summary: Pediatric movement disorders (PMDs) are common and have recently received increasing attention. As these disorders have special clinical features, the selection of appropriate behavioral assessment tools that can clearly distinguish movement disorders from other diseases (eg, epilepsy and neuromuscular disorders) is crucial for achieving an accurate diagnosis and treatment. However, few studies have focused on behavioral assessments in children. The present report attempts to provide a critical review of the available subjective and objective assessment tests for common PMDs. We believe that the principles of objectification, multi‐purpose use, and simplification are also applicable to the selection and development of satisfactory pediatric behavioral assessment tools. We expect that the development of wearable sensors, virtual reality, and augmented reality will lead to the establishment of more reliable and simple tests. In addition, more rigorous randomized controlled trials that have been specifically designed to evaluate behavioral testing in children are also expected in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis.
- Author
-
Komajda, Michel, Böhm, Michael, Borer, Jeffrey S., Ford, Ian, Tavazzi, Luigi, Pannaux, Matthieu, and Swedberg, Karl
- Subjects
HEART failure ,META-analysis ,RANDOMIZED controlled trials ,DRUG therapy ,CARDIAC arrest ,CARDIOVASCULAR agents ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL protocols ,RESEARCH ,RESEARCH funding ,SYSTEMATIC reviews ,EVALUATION research ,TREATMENT effectiveness ,STROKE volume (Cardiac output) ,THERAPEUTICS - Abstract
Aims: A network meta-analysis (NMA) of all recommended drug groups for the treatment of heart failure with reduced ejection fraction (HFrEF), including their combinations, was performed to assess the relative efficacy and incremental benefit.Methods and Results: A search was made in biomedical databases for randomized controlled trials published between 1987 and 2017 on angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers (BBs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), ivabradine (IVA), or angiotensin receptor-neprilysin inhibitors (ARNI). A total of 58 relevant trials were identified. The relative efficacy of each treatment group (or combination) in terms of all-cause mortality, cardiovascular mortality, all-cause hospitalizations and hospitalizations for heart failure, per patient-year of follow-up, were combined in a random-effects Bayesian NMA. The pairwise comparison between each regimen and for each outcome was estimated. The NMA was dominated by 15 large-scale trials with between 1984 and 18 898 patient-years of follow-up. Combinations of drug groups showed incremental benefits on outcomes over single groups. The most effective combinations were ARNI+BB + MRA and ACEI+BB + MRA + IVA, showing reductions in all-cause mortality (vs. placebo) of 62% and 59%, respectively; hazard ratios were 0.38 [credible interval (CrI) 0.20-0.65] and 0.41 (CrI 0.21-0.70); and in all-cause hospitalizations with reductions of 42% for both. These two combinations were also the most effective for the other outcomes studied.Conclusion: Our analysis shows that the incremental use of combinations of disease-modifying therapies has resulted in the progressive improvement in mortality and hospitalization outcomes in HFrEF. Our findings support the current guideline recommendations. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study.
- Author
-
Laufs, Ulrich, Griese‐Mammen, Nina, Krueger, Katrin, Wachter, Angelika, Anker, Stefan D., Koehler, Friedrich, Rettig‐Ewen, Volker, Botermann, Lea, Strauch, Dorothea, Trenk, Dietmar, Böhm, Michael, Schulz, Martin, Griese-Mammen, Nina, and Rettig-Ewen, Volker
- Subjects
HEART failure ,RANDOMIZED controlled trials ,HOSPITAL care ,OUTPATIENT medical care ,DRUG therapy ,ADRENERGIC beta blockers ,ACE inhibitors ,ANGIOTENSIN receptors ,COMBINATION drug therapy ,COMPARATIVE studies ,DRUGS ,INTERDISCIPLINARY education ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PATIENT compliance ,RESEARCH ,STATISTICAL sampling ,PILOT projects ,EVALUATION research ,TREATMENT effectiveness ,THERAPEUTICS - Abstract
We report the rationale and design of a community PHARMacy-based prospective randomized controlled interdisciplinary study for ambulatory patients with Chronic Heart Failure (PHARM-CHF) and results of its pilot study. The pilot study randomized 50 patients to a pharmacy-based intervention or usual care for 12 months. It demonstrated the feasibility of the design and showed reduced systolic blood pressure in the intervention group as indicator for improved medication adherence. The main study will randomize patients ≥60 years on stable pharmacotherapy including at least one diuretic and a history of heart failure hospitalization within 12 months. The intervention group will receive a medication review at baseline followed by regular dose dispensing of the medication, counselling regarding medication use and symptoms of heart failure. The control patients are unknown to the pharmacy and receive usual care. The primary efficacy endpoint is medication adherence, pre-specified as a significant difference of the proportion of days covered between the intervention and control group within 365 days following randomization using pharmacy claims data for three CHF medications (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists). The primary composite safety endpoint is days lost due to blindly adjudicated unplanned cardiovascular hospitalizations or death. Overall, 248 patients shall be randomized. The minimum follow-up is 12 months with an expected mean of 24 months. Based on the feasibility demonstrated in the pilot study, the randomized PHARM-CHF trial will test whether an interdisciplinary pharmacy-based intervention can safely improve medication adherence and will estimate the potential impact on clinical endpoints. ClinicalTrials.gov Identifier: NCT01692119. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus.
- Author
-
Kanwal, Fasiha, Pyne, Jeffrey M., Tavakoli‐Tabasi, Shahriar, Nicholson, Susan, Dieckgraefe, Brian, Storay, Erma, Goetz, Matthew Bidwell, Kramer, Jennifer R., Smith, Donna, Sansgiry, Shubhada, Tansel, Aylin, Gifford, Allen L., Asch, Steven M., and Tavakoli-Tabasi, Shahriar
- Subjects
CHRONIC hepatitis C ,HEPATITIS C virus ,MENTAL depression ,THERAPEUTICS ,ELECTRONIC health records ,RANDOMIZED controlled trials - Abstract
Objective: To test the effectiveness of a collaborative depression care model in improving depression and hepatitis C virus (HCV) care.Data Sources/study Setting: Hepatitis C virus clinic patients who screened positive for depression at four Veterans Affairs Hospitals.Study Design: We compared off-site depression collaborative care (delivered by depression care manager, pharmacist, and psychiatrist) with usual care in a randomized trial. Primary depression outcomes were treatment response (≥50 percent decrease in 20-item Hopkins Symptoms Checklist [SCL-20] score), remission (mean SCL-20 score, <0.5), and depression-free days (DFDs). Primary HCV outcome was receipt of HCV treatment.Data Collection: Patient data were collected by self-report telephone surveys at baseline and 12 months, and from electronic medical records.Principal Findings: Baseline screening identified 292 HCV-infected patients with depression, and 242 patients completed 12-month follow-up (82.9 percent). Intervention participants were more likely to report depression treatment response, remission, and more DFDs than usual care participants. Intervention participants were more likely to receive antiviral treatment; however, the difference was not statistically significant.Conclusion: Off-site depression collaborative care improved depression outcomes in HCV patients and may serve as a model for collaboration between mental health and specialty physical health providers in other high co-occurring conditions. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
27. Bringing population mobility into focus to achieve HIV prevention goals.
- Author
-
Camlin, Carol S., Cassels, Susan, and Seeley, Janet
- Subjects
HIV infection transmission ,HIV infections ,THERAPEUTICS ,HIGHLY active antiretroviral therapy ,RANDOMIZED controlled trials ,MEDICAL care - Abstract
The article provides information on the role of population mobility for achieving HIV infections treatment, transmission and prevention in African countries. Topics discussed include antiretroviral therapy for HIV infections, engagement in the medical care and viral suppression through various randomized controlled trials.
- Published
- 2018
- Full Text
- View/download PDF
28. Systematic review: safety of mesalazine in ulcerative colitis.
- Author
-
Sehgal, P., Colombel, J.‐F., Aboubakr, A., and Narula, N.
- Subjects
MEDICATION safety ,MESALAMINE ,ULCERATIVE colitis ,DRUG side effects ,RANDOMIZED controlled trials ,SEXUAL dysfunction ,THERAPEUTICS - Abstract
Summary: Background: Mesalazine is the most commonly prescribed medication for mild to moderate ulcerative colitis. It is generally well tolerated with some reported side effects. Aim: To summarise adverse drug events to mesalazine and recommend techniques for management. Furthermore, to determine if there is a dose‐dependent relationship between high (>2.4 g/day) vs low dosing (≤2.4 g/day) and occurrence of adverse drug events. Methods: A literature search for relevant studies from inception to 1 December 2017 of the MEDLINE database was conducted. Two reviewers screened all titles identified. Data obtained from randomised controlled trials was used to estimate incidence rates of each adverse event. Two reviewers independently assessed methodological risk of bias and performed data extraction. Results: 3581 articles were initially considered. Of these, 3573 were screened, 622 reviewed and 91 included. Adverse events attributed to mesalazine included inflammatory reactions, pancreatitis, cardiotoxicity, hepatotoxicity, musculoskeletal complaints, respiratory symptoms, nephropathies and sexual dysfunction. There does not appear to be a dose‐dependent relationship of mesalazine and occurrence of adverse events. Conclusion: Patients on mesalazine should be monitored for worsening of ulcerative colitis and development of new onset organ dysfunction. High‐dose mesalazine appears to have similar safety profile as low dose, and is not associated with greater risk of adverse events. Prior to placing a patient on mesalazine, baseline liver and renal function should be evaluated. Renal function should be periodically assessed, whereas other testing should be performed depending on development of symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Effectiveness of using a new polyurethane foam multi‐layer dressing in the sacral area to prevent the onset of pressure ulcer in the elderly with hip fractures: A pragmatic randomised controlled trial.
- Author
-
Forni, Cristiana, D'Alessandro, Fabio, Gallerani, Pina, Genco, Rossana, Bolzon, Andrea, Bombino, Caterina, Mini, Sandra, Rocchegiani, Laura, Notarnicola, Teresa, Vitulli, Arianna, Amodeo, Alfredo, Celli, Guglielmo, and Taddia, Patrizia
- Subjects
POLYURETHANES ,AGE factors in disease ,CONFIDENCE intervals ,PRESSURE ulcers ,FOAMED materials ,BONE fractures ,HIP joint injuries ,MEDICAL care costs ,SACRUM ,SURGICAL dressings ,TRANSPARENCY (Optics) ,RANDOMIZED controlled trials ,RELATIVE medical risk ,TREATMENT effectiveness ,OLD age ,PREVENTION ,THERAPEUTICS - Abstract
Hip fractures in the elderly are a serious problem for the health service due to the high rate of complications. One of these complications is pressure ulcers that, according to the literature, occur in 8.8% to 55% of patients and mainly arise in the sacral area. The present randomised controlled trial tests whether applying a new innovative multi‐layer polyurethane foam dressing (ALLEVYN LIFE™), reduces the onset of pressure ulcers in the sacral area. From March to December 2016, 359 fragility hip fracture patients were randomly divided into 2 groups: 182 in the control group and 177 in the experimental group. Pressure ulcers occurred overall in 36 patients (10%): 8 patients (4.5%) in the experimental group compared to 28 (15.4%) in the control group: P = 0.001, relative risk 0.29 (95% CI 0.14‐0.61) with NNT of 9 (95% CI 6‐21). In the experimental group the onset of pressure ulcers occurred on average on the 6th day compared to the 4th day in the control group (HR 4.4). Using polyurethane foam is effective at reducing the rate of pressure ulcers in the sacrum in elderly patients with hip fracture. The adhesiveness of this device also enables costs to be kept down. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial.
- Author
-
Zahed, Reza, Mousavi Jazayeri, Mohammad Hossain, Naderi, Asieh, Naderpour, Zeinab, and Saeedi, Morteza
- Subjects
NOSEBLEED treatment ,ASPIRIN ,BANDAGES & bandaging ,LENGTH of stay in hospitals ,HOSPITAL emergency services ,NASAL cavity ,NOSEBLEED ,PATIENT satisfaction ,CUTANEOUS therapeutics ,DISEASE relapse ,RANDOMIZED controlled trials ,DISCHARGE planning ,TREATMENT effectiveness ,CONTINUING education units ,CLOPIDOGREL ,TRANEXAMIC acid ,THERAPEUTICS - Abstract
Abstract: Objective: We evaluated the efficacy of topical application of the injectable form of tranexamic acid (TXA) compared with anterior nasal packing (ANP) for the treatment of epistaxis in patients taking antiplatelet drugs (aspirin, clopidogrel, or both) who presented to the emergency department (ED). Methods: A randomized, parallel‐group clinical trial was conducted at two EDs. A total of 124 participants were randomized to receive topical TXA (500 mg in 5 mL) or ANP, 62 patients per group. The primary outcome was the proportion of patients in each group whose bleeding had stopped at 10 minutes. Secondary outcomes were the rebleeding rate at 24 hours and 1 week, ED length of stay (LOS), and patient satisfaction. Results: Within 10 minutes of treatment, bleeding was stopped in 73% of the patients in the TXA group, compared with 29% in the ANP group (difference = 44%, 95% confidence interval, 26% to 57%; p < 0.001). Additionally, rebleeding was reported in 5 and 10% of patients during the first 24 hours in the TXA and the ANP groups, respectively. At 1 week, 5% of patients in the TXA group and 21% of patients in the ANP group had experienced recurrent bleeding (p = 0.007). Patients in the TXA group reported higher satisfaction scores (median [interquartile range {IQR}], 9 [8–9.25]) compared with the ANP group (median [IQR] = 4 [3–5]; p < 0.001). Discharge from the ED in <2 hours was achieved in 97% of patients in the TXA group versus 13% in the ANP group (p < 0.001). There were no adverse events reported in either group. Conclusions: In our study population, epistaxis treatment with topical application of TXA resulted in faster bleeding cessation, less rebleeding at 1 week, shorter ED LOS, and higher patient satisfaction compared with ANP. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. A Ketone Ester Drink Lowers Human Ghrelin and Appetite.
- Author
-
Stubbs, Brianna J., Cox, Pete J., Evans, Rhys D., Cyranka, Malgorzata, Clarke, Kieran, and de Wet, Heidi
- Subjects
KETONES ,GHRELIN ,WEIGHT loss ,DIET ,BLOOD sampling ,BEVERAGE analysis ,APPETITE ,CARBOXYLIC acids ,COMPARATIVE studies ,CROSSOVER trials ,HUNGER ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,BLIND experiment ,THERAPEUTICS - Abstract
Objective: The ketones d-β-hydroxybutyrate (BHB) and acetoacetate are elevated during prolonged fasting or during a "ketogenic" diet. Although weight loss on a ketogenic diet may be associated with decreased appetite and altered gut hormone levels, it is unknown whether such changes are caused by elevated blood ketones. This study investigated the effects of an exogenous ketone ester (KE) on appetite.Methods: Following an overnight fast, subjects with normal weight (n = 15) consumed 1.9 kcal/kg of KE, or isocaloric dextrose (DEXT), in drinks matched for volume, taste, tonicity, and color. Blood samples were analyzed for BHB, glucose, insulin, ghrelin, glucagon-like peptide 1 (GLP-1), and peptide tyrosine tyrosine (PYY), and a three-measure visual analogue scale was used to measure hunger, fullness, and desire to eat.Results: KE consumption increased blood BHB levels from 0.2 to 3.3 mM after 60 minutes. DEXT consumption increased plasma glucose levels between 30 and 60 minutes. Postprandial plasma insulin, ghrelin, GLP-1, and PYY levels were significantly lower 2 to 4 hours after KE consumption, compared with DEXT consumption. Temporally related to the observed suppression of ghrelin, reported hunger and desire to eat were also significantly suppressed 1.5 hours after consumption of KE, compared with consumption of DEXT.Conclusions: Increased blood ketone levels may directly suppress appetite, as KE drinks lowered plasma ghrelin levels, perceived hunger, and desire to eat. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
32. Behavioral Weight Loss Intervention for Migraine: A Randomized Controlled Trial.
- Author
-
Bond, Dale S., Thomas, J. Graham, Lipton, Richard B., Roth, Julie, Pavlovic, Jelena M., Rathier, Lucille, O'Leary, Kevin C., Evans, E. Whitney, Wing, Rena R., and O'Leary, Kevin C
- Subjects
MIGRAINE diagnosis ,MIGRAINE ,HEADACHE treatment ,WEIGHT loss ,WOMEN'S health ,MIGRAINE prevention ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,EVALUATION research ,RANDOMIZED controlled trials ,THERAPEUTICS - Abstract
Objective: The objective of this study was to test whether behavioral weight loss (BWL) intervention decreases headaches in women with comorbid migraine and overweight or obesity.Methods: This randomized, single-blind trial allocated women 18 to 50 years old with 4 to 20 migraine days per month and a BMI = 25.0-49.9 kg/m2 to 16 weeks of BWL (n = 54), which targeted exercise and eating behaviors for weight loss, or to migraine education control (ME, n = 56), which delivered didactic instruction on migraine and treatments. Participants completed a 4-week smartphone headache diary at baseline, posttreatment (16-20 wk), and follow-up (32-36 wk). The primary outcome was posttreatment change in migraine days per month, analyzed via linear mixed effects models.Results: Of 110 participants randomly assigned, 85 (78%) and 80 (73%) completed posttreatment and follow-up. Although the BWL group achieved greater weight loss (mean [95% CI] in kilograms) than the ME group at posttreatment (-3.8 [-2.5 to -5.0] vs. + 0.9 [-0.4 to 2.2], P < 0.001) and follow-up (-3.2 [-2.0 to -4.5] vs. + 1.1 [-0.2 to 2.4], P < 0.001), there were no significant group (BWL vs. ME) differences (mean [95% CI]) in migraine days per month at posttreatment (-3.0 [-2.0 to -4.0] vs. -4.0 [-2.9 to -5.0], P = 0.185) or follow-up (-3.8 [-2.7 to -4.8] vs. -4.4 [-3.4 to -5.5], P = 0.378).Conclusions: Contrary to hypotheses, BWL and ME yielded similar, sustained reductions in migraine headaches. Future research should evaluate whether adding BWL to standard pharmacological and/or nonpharmacological migraine treatment approaches yields greater benefits. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
33. Clinical efficacy of a topical lactic acid bacterial microbiome in chronic rhinosinusitis: A randomized controlled trial.
- Author
-
Mårtensson, Anders, Abolhalaj, Milad, Lindstedt, Malin, Mårtensson, Anette, Olofsson, Tobias C., Vásquez, Alejandra, Greiff, Lennart, and Cervin, Anders
- Subjects
HUMAN microbiota ,SINUSITIS ,NASAL polyps ,BIFIDOBACTERIUM ,RANDOMIZED controlled trials - Abstract
Objective A locally disturbed commensal microbiome might be an etiological factor in chronic rhinosinusitis (CRS) in general and in CRS without nasal polyps (CRSsNP) in particular. Lactic acid bacteria (LAB) have been suggested to restore commensal microbiomes. A honeybee LAB microbiome consisting of various lactobacilli and bifidobacteria have been found potent against CRS pathogens in vitro. Recently, we examined effects of single nasal administrations of this microbiome in healthy subjects and found it inert. In this study, we examined effects of repeated such administrations in patients with CRSsNP. Study Design The study was of a randomized, double-blinded, crossover, and sham-controlled design. Methods Twenty patients received 2 weeks' treatment administered using a nasal spray-device. The subjects were monitored with regard to symptoms (SNOT-22 questionnaire, i.e., the primary efficacy variable), changes to their microbiome, and inflammatory products (IL-6, IL-8, TNF-, IL-8,a, and MPO) in nasal lavage fluids. Results Neither symptom scores, microbiological explorations, nor levels of inflammatory products in nasal lavage fluids were affected by LAB (c.f. sham). Conclusion Two weeks' nasal administration of a honeybee LAB microbiome to patients with CRSsNP is well tolerated but affects neither symptom severity nor the microbiological flora/local inflammatory activity. Level of Evidence 1b [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
34. Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis.
- Author
-
Roldan, Carlos J., Chambers, Kimberly A., Paniagua, Linda, Patel, Sonali, Cardenas‐Turanzas, Marylou, Chathampally, Yashwant, and Miner, James R.
- Subjects
ABDOMINAL pain ,COMBINED modality therapy ,EMERGENCY medical services ,HOSPITAL emergency services ,NAUSEA ,PATIENTS ,PROBABILITY theory ,SCALE analysis (Psychology) ,PAIN measurement ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,ACUTE diseases ,DISEASE exacerbation ,HALOPERIDOL ,DESCRIPTIVE statistics ,GASTROPARESIS ,SYMPTOMS ,THERAPEUTICS - Abstract
Objective: Gastroparesis is a debilitating condition that causes nausea, vomiting, and abdominal pain. Management includes analgesics and antiemetics, but symptoms are often refractory. Haloperidol has been utilized in the palliative care setting for similar symptoms. The study objective was to determine whether haloperidol as an adjunct to conventional therapy would improve symptoms in gastroparesis patients presenting to the emergency department (ED). Study Design and Methods: This was a randomized, double-blind, placebo-controlled trial of adult ED patients with acute exacerbation of previously diagnosed gastroparesis. The treatment group received 5 mg of haloperidol plus conventional therapy (determined by the treating physician). The control group received a placebo plus conventional therapy. The severity of each subject’s abdominal pain and nausea were assessed before intervention and every 15 minutes thereafter for 1 hour using a 10-point scale for pain and a 5-point scale for nausea. Primary outcomes were decreased pain and nausea 1 hour after treatment. Results: Of the 33 study patients, 15 were randomized to receive haloperidol. Before treatment, the mean intensity of pain was 8.5 in the haloperidol group and 8.28 in the placebo group; mean pretreatment nausea scores were 4.53 and 4.11, respectively. One hour after therapy, the mean pain and nausea scores in the haloperidol group were 3.13 and 1.83 compared to 7.17 and 3.39 in the placebo group. The reduction in mean pain intensity therapy was 5.37 in the haloperidol group (p ≤ 0.001) compared to 1.11 in the placebo group (p = 0.11). The reduction in mean nausea score was 2.70 in the haloperidol group (p ≤ 0.001) and 0.72 in the placebo group (p = 0.05). Therefore, the reductions in symptom scores were statistically significant in the haloperidol group but not in the placebo group. No adverse events were reported. Conclusions: Haloperidol as an adjunctive therapy is superior to placebo for acute gastroparesis symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
35. Effectiveness of a decision aid for patients with depression: A randomized controlled trial.
- Author
-
Perestelo ‐ Perez, Lilisbeth, Rivero ‐ Santana, Amado, Sanchez ‐ Afonso, Juan Antonio, Perez ‐ Ramos, Jeanette, Castellano ‐ Fuentes, Carmen Luisa, Sepucha, Karen, and Serrano ‐ Aguilar, Pedro
- Subjects
ANTIDEPRESSANTS ,MENTAL depression ,THERAPEUTICS ,CHI-squared test ,MEDICINE information services ,PROBABILITY theory ,PSYCHOLOGICAL tests ,REGRESSION analysis ,RESEARCH funding ,T-test (Statistics) ,WORLD Wide Web ,LOGISTIC regression analysis ,RANDOMIZED controlled trials ,DATA analysis software ,HEALTH information services ,ODDS ratio - Abstract
Background Shared decision making is an important component of patient-centred care and decision aids are tools designed to support patients' decision making and help patients with depression to make informed choices. Objective The study aim was to assess the effectiveness of a web-based decision aid for patients with unipolar depression. Design Randomized controlled trial. Setting and participants Adults diagnosed with a major depressive disorder and recruited in primary care centres were included and randomized to the decision aid (n=68) or usual care (n=79). Intervention Patients in the decision aid group reviewed the decision aid accompanied by a researcher. Outcome measures Knowledge about treatment options, decisional conflict, treatment intention and preference for participation in decision making. We also developed a pilot measure of concordance between patients' goals and concerns about treatment options and their treatment intention. Results Intervention significantly improved knowledge ( P<.001) and decisional conflict ( P<.001), and no differences were observed in treatment intention, preferences for participation, or concordance. One of the scales developed to measure goals and concerns showed validity issues. Conclusion The decision aid 'Decision making in depression' is effective improving knowledge of treatment options and reducing decisional conflict of patients with unipolar depression. More research is needed to establish a valid and reliable measure of concordance between patients' goals and concerns regarding pharmacological and psychological treatment, and the choice made. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
36. Big conductance calcium-activated potassium channel openers control spasticity without sedation.
- Author
-
Baker, David, Pryce, Gareth, Visintin, Cristina, Sisay, Sofia, Bondarenko, Alexander I, Vanessa Ho, W S, Jackson, Samuel J, Williams, Thomas E, Al ‐ Izki, Sarah, Sevastou, Ioanna, Okuyama, Masahiro, Graier, Wolfgang F, Stevenson, Lesley A, Tanner, Carolyn, Ross, Ruth, Pertwee, Roger G, Henstridge, Christopher M, Irving, Andrew J, Schulman, Jesse, and Powell, Keith
- Subjects
CANNABINOIDS ,MULTIPLE sclerosis ,CANNABIS (Genus) ,ANANDAMIDE ,SPASTICITY ,MESENTERIC artery physiology ,PHARMACOKINETICS ,VAS deferens physiology ,DRUG therapy ,ANIMAL experimentation ,BENZAMIDE ,CELL receptors ,CHEMISTRY ,COMPARATIVE studies ,DEMYELINATION ,DOGS ,DRUGS ,EPITHELIAL cells ,RESEARCH methodology ,MEDICAL cooperation ,MEMBRANE proteins ,MESENTERIC artery ,MICE ,NEUROTRANSMITTERS ,PRIMATES ,RABBITS ,RATS ,RESEARCH ,RESEARCH funding ,VAS deferens ,EVALUATION research ,RANDOMIZED controlled trials ,BLIND experiment ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
Background and Purpose: Our initial aim was to generate cannabinoid agents that control spasticity, occurring as a consequence of multiple sclerosis (MS), whilst avoiding the sedative side effects associated with cannabis. VSN16R was synthesized as an anandamide (endocannabinoid) analogue in an anti-metabolite approach to identify drugs that target spasticity.Experimental Approach: Following the initial chemistry, a variety of biochemical, pharmacological and electrophysiological approaches, using isolated cells, tissue-based assays and in vivo animal models, were used to demonstrate the activity, efficacy, pharmacokinetics and mechanism of action of VSN16R. Toxicological and safety studies were performed in animals and humans.Key Results: VSN16R had nanomolar activity in tissue-based, functional assays and dose-dependently inhibited spasticity in a mouse experimental encephalomyelitis model of MS. This effect occurred with over 1000-fold therapeutic window, without affecting normal muscle tone. Efficacy was achieved at plasma levels that are feasible and safe in humans. VSN16R did not bind to known CB1 /CB2 /GPPR55 cannabinoid-related receptors in receptor-based assays but acted on a vascular cannabinoid target. This was identified as the major neuronal form of the big conductance, calcium-activated potassium (BKCa ) channel. Drug-induced opening of neuronal BKCa channels induced membrane hyperpolarization, limiting excessive neural-excitability and controlling spasticity.Conclusions and Implications: We identified the neuronal form of the BKCa channel as the target for VSN16R and demonstrated that its activation alleviates neuronal excitability and spasticity in an experimental model of MS, revealing a novel mechanism to control spasticity. VSN16R is a potential, safe and selective ligand for controlling neural hyper-excitability in spasticity. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
37. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine for treatment of malaria infection in pregnancy in Ghana: an open-label, randomised, non-inferiority trial.
- Author
-
Osarfo, Joseph, Tagbor, Harry, Cairns, Matthew, Alifrangis, Michael, and Magnussen, Pascal
- Subjects
MALARIA in pregnancy ,AMODIAQUINE ,INFECTION ,VOMITING ,DIZZINESS ,QUINOLINE ,ANTIMALARIALS ,COMMUNICABLE diseases ,COMPARATIVE studies ,RESEARCH methodology ,EVALUATION of medical care ,MEDICAL cooperation ,PREGNANCY ,PREGNANCY complications ,RESEARCH ,RESEARCH funding ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,THERAPEUTICS - Abstract
Copyright of Tropical Medicine & International Health is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
38. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
- Author
-
Volkmann, Elizabeth R., Tashkin, Donald P., Li, Ning, Roth, Michael D., Khanna, Dinesh, Hoffmann‐Vold, Anna‐Maria, Kim, Grace, Goldin, Jonathan, Clements, Philip J., Furst, Daniel E., and Elashoff, Robert M.
- Subjects
DIAGNOSIS of dyspnea ,CYCLOPHOSPHAMIDE ,MYCOPHENOLIC acid ,TREATMENT effectiveness ,CLINICAL trials ,INTERSTITIAL lung diseases ,LONGITUDINAL method ,PROBABILITY theory ,RESPIRATORY measurements ,STATISTICAL sampling ,SYSTEMIC scleroderma ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics ,DISEASE complications ,THERAPEUTICS - Abstract
Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of systemic sclerosis (SSc)-related interstitial lung disease (ILD). Methods We included participants enrolled in the placebo arm of Scleroderma Lung Study (SLS) I and the MMF arm of SLS II. SLS I randomized participants to receive either oral cyclophosphamide (CYC) or placebo for 1 year, while SLS II randomized participants to receive either MMF for 2 years or oral CYC for 1 year followed by 1 year of placebo. Eligibility criteria for SLS I and SLS II were nearly identical. The primary outcome was % predicted forced vital capacity (FVC), and key secondary outcomes included % predicted diffusing capacity for carbon monoxide (DL co), the modified Rodnan skin thickness score (MRSS), and dyspnea. Joint models were created to evaluate the treatment effect on the course of these outcomes over 2 years. Results At baseline, the MMF-treated group in SLS II (n = 69) and the placebo-treated group in SLS I (n = 79) had similar percentages of men and women and similar disease duration, SSc subtype, extent of skin disease, and % predicted FVC. MMF-treated patients in SLS II were slightly older (mean ± SD age 52.6 ± 9.7 years versus 48.1 ± 12.4 years; P = 0.0152) and had higher % predicted DL co (mean ± SD 54.0 ± 11.1 versus 46.2 ± 13.3; P = 0.0002) than placebo-treated patients in SLS I. After adjustment for baseline disease severity, treatment with MMF in comparison with placebo was associated with improved % predicted FVC ( P < 0.0001), % predicted DL co ( P < 0.0001), MRSS ( P < 0.0001), and dyspnea ( P = 0.0112) over 2 years. Conclusion Although there are inherent limitations in comparing participants from different trials, treatment with MMF was associated with improvements in physiologic outcomes and dyspnea compared with placebo, even after accounting for baseline disease severity. These results further substantiate the use of MMF for the treatment of SSc-related ILD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.
- Author
-
Currò, Diego, Ianiro, Gianluca, Pecere, Silvia, Bibbò, Stefano, Cammarota, Giovanni, Currò, Diego, and Bibbò, Stefano
- Subjects
INFLAMMATORY bowel disease treatment ,PROBIOTICS ,HERBAL medicine ,RANDOMIZED controlled trials ,FUNCTIONAL foods ,THERAPEUTICS ,ANIMALS ,BIOLOGICAL products ,CONSTIPATION ,DIETARY supplements ,DIETARY fiber ,INFLAMMATORY bowel diseases ,IRRITABLE colon ,QUALITY of life ,PREBIOTICS ,FERRANS & Powers Quality of Life Index ,IMPACT of Event Scale - Abstract
Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also called chronic idiopathic constipation), are very common worldwide. Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, although less common, has a strong impact on patients' quality of life, as well as being highly expensive for our healthcare. A definite cure for those disorders is still yet to come. Over the years, several therapeutic approaches complementary or alternative to traditional pharmacological treatments, including probiotics, prebiotics, synbiotics, fibre and herbal medicinal products, have been investigated for the management of both groups of diseases. However, most available studies are biased by several drawbacks, including small samples and poor methodological quality. Probiotics, in particular Saccharomyces boulardii and Lactobacilli (among which Lactobacillus rhamnosus), synbiotics, psyllium, and some herbal medicinal products, primarily peppermint oil, seem to be effective in ameliorating IBS symptoms. Synbiotics and fibre seem to be beneficial in FC patients. The probiotic combination VSL#3 may be effective in inducing remission in patients with mild-to-moderate ulcerative colitis, in whom Escherichia coli Nissle 1917 seems to be as effective as mesalamine in maintaining remission. No definite conclusions can be drawn as to the efficacy of fibre and herbal medicinal products in IBD patients due to the low number of studies and the lack of randomized controlled trials that replicate the results obtained in the individual studies conducted so far. Thus, further, well-designed studies are needed to address the real role of these therapeutic options in the management of both FBD and IBD.
Linked Articles: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
40. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
- Author
-
Sanyal, A. J., Boyer, T. D., Frederick, R. T., Wong, F., Rossaro, L., Araya, V., Vargas, H. E., Reddy, K. R., Pappas, S. C., Teuber, P., Escalante, S., and Jamil, K.
- Subjects
HEPATORENAL syndrome ,VASOCONSTRICTORS ,PLACEBOS ,BILIRUBIN ,RANDOMIZED controlled trials ,THERAPEUTICS - Abstract
Background The goal of hepatorenal syndrome type 1 ( HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available. Aim To compare the efficacy of terlipressin plus albumin vs. placebo plus albumin in patients with HRS-1. Methods Pooled patient-level data from two large phase 3, randomised, placebo-controlled studies were analysed for HRS reversal [serum creatinine ( SCr) value ≤133 μmol/L], 90-day survival, need for renal replacement therapy and predictors of HRS reversal. Patients received intravenous terlipressin 1-2 mg every 6 hours plus albumin or placebo plus albumin up to 14 days. Results The pooled analysis comprised 308 patients (terlipressin: n = 153; placebo: n = 155). HRS reversal was significantly more frequent with terlipressin vs. placebo (27% vs. 14%; P = 0.004). Terlipressin was associated with a more significant improvement in renal function from baseline until end of treatment, with a mean between-group difference in SCr concentration of −53.0 μmol/L ( P < 0.0001). Lower SCr, lower mean arterial pressure and lower total bilirubin and absence of known precipitating factors for HRS were independent predictors of HRS reversal and longer survival in terlipressin-treated patients. Conclusions Terlipressin plus albumin resulted in a significantly higher rate of HRS reversal vs. albumin alone in patients with HRS-1. Terlipressin treatment is associated with improved renal function. (ClinicalTrials.gov identifier: OT-0401, NCT00089570; REVERSE, NCT01143246). [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
41. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.
- Author
-
Smith, Steven R., Garvey, W. Timothy, Greenway, Frank L., Zhou, Sharon, Fain, Randi, Pilson, Robert, Fujioka, Ken, and Aronne, Louis J.
- Subjects
PHENTERMINE (Drug) ,ANTIOBESITY agents ,REGULATION of body weight ,DRUG tolerance ,DISEASE incidence ,AMPHETAMINES ,COMPARATIVE studies ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,WEIGHT loss ,PILOT projects ,EVALUATION research ,RANDOMIZED controlled trials ,BLIND experiment ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
Objective: To assess the short-term tolerability of lorcaserin alone or with two dose regimens of phentermine.Methods: This was a 12-week, randomized, double-blind, pilot safety study of N = 238 nondiabetic patients with obesity or overweight with ≥1 comorbidity randomized to lorcaserin 10 mg twice daily (BID; LOR BID) alone or with phentermine 15 mg once daily (QD; LOR BID+PHEN QD) or 15 mg twice daily (LOR BID+PHEN BID). Patients reporting ≥ 1 of 9 potentially serotonergic adverse events (AEs), mean weight loss (WL), and ≥5% WL are reported.Results: N = 238 were randomized, and N = 235 were treated. N = 94 reported potentially serotonergic AEs: 37.2% LOR BID, 42.3% LOR BID+PHEN QD, and 40.5% LOR BID+PHEN BID. AEs leading to discontinuation were reported approximately twice as often in the LOR BID+PHEN BID group versus the LOR BID group. Mean WL was 3.5 kg/3.3%, 7.0 kg/6.7%, and 7.6 kg/7.2% for LOR BID, LOR BID+PHEN QD, and LOR BID+PHEN BID, respectively. At least 5% WL was achieved by 28.2% LOR BID, 59.0% LOR BID+PHEN QD (P = 0.0002 vs. LOR BID), and 70.9% LOR BID+PHEN BID (P < 0.0001 vs. LOR BID) patients.Conclusions: Phentermine added to lorcaserin enhanced short-term weight loss but did not increase incidence of potentially serotonergic AEs; however, phentermine twice daily increased discontinuation compared to both lorcaserin alone and lorcaserin plus phentermine once daily. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
42. Self-management interventions in pediatric epilepsy: What is the level of evidence?
- Author
-
Wagner, Janelle L., Modi, Avani C., Johnson, Erica K., Shegog, Ross, Escoffery, Cam, Bamps, Yvan, Austin, Joan K., Schultz, Rebecca J., MapelLentz, Sarah, and Smith, Gigi
- Subjects
CHILDHOOD epilepsy ,SELF-management (Psychology) ,RANDOMIZED controlled trials ,MENTAL health services ,THERAPEUTICS - Abstract
Objective To respond to recommendations put forth by the Institute of Medicine to improve self-management resources for youth with epilepsy by conducting a systematic review of the self-management literature in pediatric epilepsy. Methods Inclusion criteria: youth birth to 18 years with a seizure disorder or an epilepsy diagnosis and/or their caregivers, published 1985-2014 in English, and conducted in countries with a very high human development index. Abstract and keywords had to explicitly refer to 'self-care' (pre-1996) and/or self-management (post-1996). The review was conducted in seven phases: (1) identification of bibliographical search criteria and databases; (2) abstract assessment; (3) full article review; (4) organization of final citations into instrument development, intervention, factors associated with self-management categories; (5) American Academy of Neurology level of evidence ( LOE) assessment for intervention studies; (6) CONsolidated Standards of Reporting Trials (CONSORT) evaluation of LOE level III articles utilizing a control group; and (7) categorization of intervention outcomes across four self-management domains. Results Of the 87 articles that met eligibility criteria, 24 were interventions and received LOE scores of level III or IV. Most studies (n = 20, 80%) were scored at level III; however, only eight had a control group and adhered to CONSORT guidelines. They largely neglected information on intervention components (e.g., implementation, treatment fidelity), randomization, participant flow, missing data, and effect size or confidence intervals. The 24 intervention studies reported significant impact in four domains: individual (n = 13), family (n = 6), health care system (n = 3), and community (n = 2). Significance There are no level I or II studies. No study met full CONSORT guidelines. Outcomes were well described; however, the nature of self-management interventions (e.g., multiple foci, skills targeted) and the observed heterogeneity in outcomes complicates comparisons across studies. Randomized controlled trials ( RCTs) that include large sample sizes, impact of the intervention, treatment fidelity, and power analyses are necessary to further this evidence base. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
43. Internet-delivered obesity treatment improves symptoms of and risk for depression.
- Author
-
Naparstek, Jacob, Wing, Rena R., Xu, Xiaomeng, and Leahey, Tricia M.
- Subjects
MENTAL depression risk factors ,WEIGHT loss ,OBESITY ,METABOLIC disorders ,NUTRITION disorders ,TYPE 2 diabetes ,METABOLIC syndrome ,THERAPEUTICS ,OBESITY & psychology ,OBESITY treatment ,COMPARATIVE studies ,MENTAL depression ,HEALTH promotion ,INTERNET ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,RESIDENTIAL patterns ,SOCIAL support ,EVALUATION research ,LIFESTYLES ,RANDOMIZED controlled trials ,TREATMENT effectiveness - Abstract
Objective: In-person lifestyle interventions for obesity treatment yield significant improvements in depression. These improvements may be attributed to the excellent weight losses produced by in-person interventions. In contrast, Internet programs yield more modest weight losses, and their effect on depression is unknown. This study is the first to examine whether Internet-delivered obesity treatment impacts depressive symptoms.Methods: Participants (N = 136) were randomized to either a community campaign plus Internet behavioral weight loss (IBWL) or community campaign alone (Control). IBWL did not include online social support components. A measure of depressive symptoms was administered, and weight was objectively assessed.Results: Of the total sample, 24% met the clinical cutoff for elevated depression risk at baseline. IBWL participants lost more weight during treatment (P = 0.005) and experienced significantly greater improvements in depressive symptoms (P = 0.02). Among participants who met the clinical cutoff for elevated risk for depression at baseline, those assigned to IBWL had greater improvements in depressive symptoms during treatment compared to Control (P = 0.033). Consequently, at post-treatment, a smaller percentage of IBWL participants were at elevated risk for depression.Conclusions: This study is the first to show that Internet-delivered obesity treatment improves depression risk and depressive symptoms in individuals with overweight or obesity. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
44. Oligofructose decreases serum lipopolysaccharide and plasminogen activator inhibitor-1 in adults with overweight/obesity.
- Author
-
Parnell, Jill A., Klancic, Teja, and Reimer, Raylene A.
- Subjects
FRUCTOOLIGOSACCHARIDES ,FIBRINOLYTIC agents ,OVERWEIGHT teenagers ,OBESITY risk factors ,LIPOPOLYSACCHARIDE structure ,HEALTH ,OBESITY complications ,BLOOD coagulation factors ,COMPARATIVE studies ,INFLAMMATION ,INFLAMMATORY mediators ,INTERLEUKINS ,OLIGOSACCHARIDES ,RESEARCH methodology ,MEDICAL cooperation ,OBESITY ,RESEARCH ,RESEARCH funding ,TUMOR necrosis factors ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PREBIOTICS ,BLIND experiment ,ADIPONECTIN ,LIPOPOLYSACCHARIDES ,DISEASE complications ,THERAPEUTICS - Abstract
Objective: To determine the effect of prebiotic supplementation on metabolic endotoxemia and systemic inflammation in adults with overweight and obesity.Methods: Samples from a previously conducted randomized, double-blind, placebo-controlled trial were used for analysis. Participants were randomized to 21 g of oligofructose (n = 20; BMI 30.4 kg/m2 ) or a maltodextrin placebo (n = 17; BMI 29.5 kg/m2 ) for 12 weeks. A total of 37 participants had samples available for the current analysis. Resistin, adiponectin, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and macrophage chemoattractant protein-1 (MCP-1) were quantified using MILLIPLEX® assays. Lipopolysaccharide (LPS) was measured using PyroGene™ Recombinant Factor C Assay.Results: Plasma LPS concentrations were reduced by 40% in the oligofructose group over 12 weeks compared to a 48% increase in the placebo group (P = 0.04). PAI-1, a risk factor for thrombosis, was reduced to a greater extent in the oligofructose group (-17.3 ± 2.6 ng/ml) compared to the placebo group (-9.7 ± 1.8 ng/ml; P = 0.03). Oligofructose did not affect IL-6, TNF-α, MCP-1, adiponectin, or resistin.Conclusions: Oligofructose reduces metabolic endotoxemia and PAI-1. Incorporating prebiotics into the diet through supplements or functional foods may help mitigate some markers of obesity-associated inflammation. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
45. A health advocacy intervention for adolescents with intellectual disability: a cluster randomized controlled trial.
- Author
-
Lennox, Nicholas, McPherson, Lyn, Bain, Chris, O'Callaghan, Michael, Carrington, Suzanne, and Ware, Robert S
- Subjects
INTELLECTUAL disabilities ,HEALTH education ,HEALTH promotion ,MENTAL health of teenagers ,RANDOMIZED controlled trials ,THERAPEUTICS ,COMPARATIVE studies ,HEALTH status indicators ,RESEARCH methodology ,MEDICAL cooperation ,PEOPLE with intellectual disabilities ,HEALTH outcome assessment ,PAMPHLETS ,POCKET computers ,PREVENTIVE health services ,RESEARCH ,SCHOOL health services ,EVALUATION research - Abstract
Aim: Adolescents with intellectual disability experience poorer heath than their peers in the general population, partially due to communication barriers and knowledge gaps in their health history. This study aimed to test a health intervention package against usual care for a range of health promotion and disease detection outcomes.Method: A parallel-group cluster randomized controlled trial was conducted with Australian adolescents with intellectual disability living in the community. Randomization occurred at school level. The intervention package consisted of classroom-based health education, a hand-held personalized health record, and a health check. Evidence of health promotion, disease prevention, and case-finding activities were extracted from general practitioners' records for 12 months post-intervention.Results: Clinical data was available for 435 of 592 (73.5%) participants from 85 schools. Adolescents allocated to receive the health intervention were more likely to have their vision (odds ratio [OR] 3.3; 95% confidence interval [CI] 1.8-6.1) and hearing (OR 2.7; 95% CI 1.0-7.3) tested, their blood pressure checked (OR 2.4; 95% CI 1.6-3.7), and weight recorded (OR 4.8; 95% CI 3.1-7.6). There was no difference between health intervention and usual care for identification of new diseases.Interpretation: The school-based intervention package increased healthcare activity in adolescents with intellectual disability living in the community. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
46. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
- Author
-
Magnani, Giulia, Giugliano, Robert P., Ruff, Christian T., Murphy, Sabina A., Nordio, Francesco, Metra, Marco, Moccetti, Tiziano, Mitrovic, Veselin, Shi, Minggao, Mercuri, Michele, Antman, Elliott M., and Braunwald, Eugene
- Subjects
THIAZOLES ,WARFARIN ,DRUG therapy ,HEART failure treatment ,ATRIAL fibrillation treatment ,VITAMIN K ,DRUG efficacy ,MEDICATION safety ,THERAPEUTICS ,VITAMIN therapy ,ANTICOAGULANTS ,PYRIDINE ,STROKE prevention ,ATRIAL fibrillation ,COMPARATIVE studies ,HEART failure ,HEMORRHAGE ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICAL sampling ,STROKE ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PROPORTIONAL hazards models ,BLIND experiment ,DISEASE complications - Abstract
Aims: In the ENGAGE AF-TIMI 48 trial, edoxaban, a factor Xa inhibitor, was not found to be inferior to warfarin for the prevention of stroke or systemic embolic events (SEE) in patients with atrial fibrillation (AF) and was associated with significantly less bleeding. The higher-dose edoxaban regimen (HDER; 60 mg dose-reduced to 30 mg once daily) has been approved in various countries in Europe, the USA, and Japan. Among patients treated with vitamin K antagonists (VKAs), symptomatic heart failure (HF) is an independent risk factor for lower time-in-therapeutic range, which reduces the efficacy and safety of VKA therapy. We evaluated the efficacy and safety of edoxaban compared with warfarin across the spectrum of HF severity in the ENGAGE AF-TIMI 48 trial.Methods and Results: Of 14 071 patients randomized to well-controlled warfarin or the HDER, 5926 (42%) had no history of HF, 6344 (45%) were in New York Heart Association (NYHA) class I-II, and 1801 (13%) were in NYHA class III-IV. The efficacy of edoxaban compared with warfarin in preventing stroke/SEE was similar in patients without and with HF regardless of the severity of HF; [HDER vs. warfarin: No-HF: hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.69-1.11; NYHA class I-II: HR 0.88, 95% CI 0.69-1.12; NYHA class III-IV: HR 0.83, 95% CI 0.55-1.25; Pinteraction = 0.97]. Compared with warfarin, HDER was consistently associated with lower risk of major bleeding (No-HF: HR 0.82, 95% CI 0.68-0.99; NYHA class I-II: HR 0.79, 95% CI 0.65-0.96; NYHA class III-IV: HR 0.79, 95% CI 0.54-1.17; Pinteraction = 0.96).Conclusion: The relative efficacy and safety of HDER compared with well-managed warfarin in AF patients with HF were similar to those without HF. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
47. Procedure-related complications of open vs endoscopic fetal surgery for treatment of spina bifida in an era of intrauterine myelomeningocele repair: systematic review and meta-analysis.
- Author
-
Araujo Júnior, E., Eggink, A. J., van den Dobbelsteen, J., Martins, W. P., and Oepkes, D.
- Subjects
SPINA bifida ,MYELOMENINGOCELE ,FETAL surgery ,ENDOSCOPIC surgery complications ,RANDOMIZED controlled trials ,META-analysis ,THERAPEUTICS ,FETOSCOPY ,SURGICAL complications ,SYSTEMATIC reviews ,TREATMENT effectiveness - Abstract
Copyright of Ultrasound in Obstetrics & Gynecology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
- Full Text
- View/download PDF
48. Injection frequency of botulinum toxin A for spastic equinus: a randomized clinical trial.
- Author
-
Hastings‐Ison, Tandy, Blackburn, Christine, Rawicki, Barry, Fahey, Michael, Simpson, Pam, Baker, Richard, and Graham, Kerr
- Subjects
EQUINUS deformity ,BOTULINUM A toxins ,CHILDREN with cerebral palsy ,HEALTH outcome assessment ,GAIT in humans ,CLINICAL drug trials ,HEALTH ,THERAPEUTICS ,BOTULINUM toxin ,MUSCLE relaxants ,CEREBRAL palsy ,COMPARATIVE studies ,FUNCTIONAL assessment ,GAIT disorders ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,NEUROLOGIC examination ,NEUROLOGICAL disorders ,QUALITY of life ,RESEARCH ,EVALUATION research ,RANDOMIZED controlled trials ,BLIND experiment ,DISEASE complications ,PSYCHOLOGY - Abstract
Aim: We compared two botulinum toxin A (BoNT-A) injection frequency regimens, 12-monthly versus 4-monthly, for spastic equinus in a randomized clinical trial. The primary outcome measure was passive ankle dorsiflexion.Method: Forty-two ambulant children with spastic equinus, secondary to cerebral palsy (23 males and 19 females; mean age 3y 6mo, SD 13mo; GMFCS levels I [n=20], II [n=19], III [n=3]) were randomized to receive either 12-monthly or 4-monthly BoNT-A injections to the calf, over a 26-month period. Twenty-one children had spastic hemiplegia, 21 children had spastic diplegia. A fixed 6U/kg dose of Botox was injected into the gastrocnemius muscle of both limbs in children with diplegia and the gastrocsoleus of the affected limb in children with hemiplegia, under mask anaesthesia.Results: Forty-two children entered the trial with 21 participants randomized to each group. There were three withdrawals and two children received serial casting midway through the trial. There was no significant difference in passive dorsiflexion between 12-monthly and 4-monthly regimens (p=0.41). There were also no significant between group differences on secondary outcome measures. There were no serious adverse events - the rate was 1.2 adverse events per child per year in the 12-monthly group and 2.2 adverse events per child per year in the 4-monthly group. Subgroup analysis revealed a significant difference in passive dorsiflexion between children with hemiplegia and diplegia (p=0.01).Interpretation: There was no significant difference between 12-monthly and 4-monthly injection regimens on passive dorsiflexion or secondary outcome measures. BoNT-A injections for spastic equinus may be recommended on a 12-monthly basis. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
49. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials.
- Author
-
Jankowska, Ewa A., Tkaczyszyn, Michał, Suchocki, Tomasz, Drozd, Marcin, von Haehling, Stephan, Doehner, Wolfram, Banasiak, Waldemar, Filippatos, Gerasimos, Anker, Stefan D., and Ponikowski, Piotr
- Subjects
INTRAVENOUS therapy ,THERAPEUTIC use of iron ,IRON deficiency ,HEART failure patients ,META-analysis ,RANDOMIZED controlled trials ,THERAPEUTICS ,CARDIOVASCULAR disease related mortality ,HEART disease complications ,TRACE elements ,CAUSES of death ,DEFICIENCY diseases ,HOSPITAL care ,IRON ,MORTALITY ,QUALITY of life ,DISEASE progression ,EXERCISE tolerance ,ODDS ratio ,DISEASE complications - Abstract
Aims: The aim of this study was to assess the net clinical and prognostic effects of intravenous (i.v.) iron therapy in patients with systolic heart failure (HF) and iron deficiency (ID).Methods and Results: We performed an aggregate data meta-analysis (random effects model) of randomized controlled trials that evaluated the effects of i.v. iron therapy in iron-deficient patients with systolic HF. We searched electronic databases up to September 2014. We identified five trials which fulfilled the inclusion criteria (509 patients received i.v. iron therapy in comparison with 342 controls). Intravenous iron therapy has been shown to reduce the risk of the combined endpoint of all-cause death or cardiovascular hospitalization [odds ratio (OR) 0.44, 95% confidence interval (CI) 0.30-0.64, P < 0.0001], and the combined endpoint of cardiovascular death or hospitalization for worsening HF (OR 0.39, 95% CI 0.24-0.63, P = 0.0001). Intravenous iron therapy resulted in a reduction in NYHA class (data are reported as a mean net effect with 95% CIs for all continuous variables) (-0.54 class, 95% CI -0.87 to -0.21, P = 0.001); an increase in 6-min walking test distance (+31 m, 95% CI 18-43, P < 0.0001); and an improvement in quality of life [Kansas City Cardiomyopathy Questionnaire (KCCQ) score +5.5 points, 95% CI 2.8-8.3, P < 0.0001; European Quality of Life-5 Dimensions (EQ-5D) score +4.1 points, 95% CI 0.8-7.3, P = 0.01; Minnesota Living With Heart Failure Questionnaire (MLHFQ) score -19 points, 95% CI:-23 to -16, P < 0.0001; and Patient Global Assessment (PGA) +0.70 points, 95% CI 0.31-1.09, P = 0004].Conclusion: The evidence indicates that i.v. iron therapy in iron-deficient patients with systolic HF improves outcomes, exercise capacity, and quality of life, and alleviates HF symptoms. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
50. Effect of dietary n-3 PUFA supplementation on the muscle transcriptome in older adults.
- Author
-
Yoshino, Jun, Smith, Gordon I., Kelly, Shannon C., Julliand, Sophie, Reeds, Dominic N., and Mittendorfer, Bettina
- Subjects
UNSATURATED fatty acids ,MUSCLE mass ,PROTEOLYSIS ,SKELETAL muscle ,GENE expression ,RANDOMIZED controlled trials ,THERAPEUTICS - Abstract
Dietary fish oil-derived n-3 PUFA supplementation can increase muscle mass, reduce oxygen demand during physical activity, and improve physical function (muscle strength and power, and endurance) in people. The results from several studies conducted in animals suggest that the anabolic and performance-enhancing effects of n-3 PUFA are at least in part transcriptionally regulated. The effect of n-3 PUFA therapy on the muscle transcriptome in people is unknown. In this study, we used muscle biopsy samples collected during a recently completed randomized controlled trial that found that n-3 PUFA therapy increased muscle mass and function in older adults to provide a comprehensive assessment of the effect of n-3 PUFA therapy on the skeletal muscle gene expression profile in these people. Using the microarray technique, we found that several pathways involved in regulating mitochondrial function and extracellular matrix organization were increased and pathways related to calpain- and ubiquitin-mediated proteolysis and inhibition of the key anabolic regulator mTOR were decreased by n-3 PUFA therapy. However, the effect of n-3 PUFA therapy on the expression of individual genes involved in regulating mitochondrial function and muscle growth, assessed by quantitative RT- PCR, was very small. These data suggest that n-3 PUFA therapy results in small but coordinated changes in the muscle transcriptome that may help explain the n-3 PUFA-induced improvements in muscle mass and function. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.